Trial Profile

A phase 2/3 randomized, open-label, controlled, parallel-arm study of Ampligen in patients with advanced or metastatic late-stage pancreatic cancer

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 18 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Mar 2026 According to an AIM ImmunoTech media release, the company announced an agreement with the PPD clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical trial .
19 Oct 2021 According to an AIM ImmunoTech media release, the company has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the USA Food and Drug Administration (FDA) for this study.
04 Oct 2021 According to an AIM ImmunoTech media release, Prof. Kelsey Klute is the study's principal investigator in the United States.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com